Benitec Biopharma Ownership

BNTC Stock  USD 12.71  1.30  11.39%   
Benitec Biopharma holds a total of 19.82 Million outstanding shares. 30% of Benitec Biopharma Ltd outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2015-03-31
Previous Quarter
21.3 M
Current Value
22.1 M
Avarage Shares Outstanding
M
Quarterly Volatility
36.3 M
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Benitec Biopharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Benitec Biopharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Benitec Stock Ownership Analysis

About 46.0% of the company shares are held by institutions such as insurance companies. The book value of Benitec Biopharma was currently reported as 4.68. The company recorded a loss per share of 5.51. Benitec Biopharma last dividend was issued on the 18th of November 2019. The entity had 1:17 split on the 26th of July 2023. Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company was incorporated in 1995 and is headquartered in Hayward, California. Benitec Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 18 people. For more info on Benitec Biopharma Ltd please contact the company at 510 780 0819 or go to https://benitec.com.

Benitec Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Benitec Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Benitec Biopharma Ltd backward and forwards among themselves. Benitec Biopharma's institutional investor refers to the entity that pools money to purchase Benitec Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Lion Point Capital, Lp2024-12-31
62 K
Myda Advisors Llc2024-12-31
50 K
Morgan Stanley - Brokerage Accounts2024-12-31
42.4 K
Northern Trust Corp2024-12-31
38.2 K
683 Capital Management Llc2024-12-31
35.8 K
Ameriprise Financial Inc2024-12-31
35.5 K
Susquehanna International Group, Llp2024-12-31
24.8 K
Qube Research & Technologies2024-12-31
20.9 K
State Street Corp2024-12-31
16.1 K
Suvretta Capital Management, Llc2024-12-31
M
Franklin Resources Inc2024-12-31
2.9 M
Note, although Benitec Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Benitec Biopharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Benitec Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Benitec Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Benitec Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Mukadam Sophie over a month ago
Insider Trading
 
Suvretta Capital Management, Llc over two months ago
Acquisition by Suvretta Capital Management, Llc of 24360 shares of Benitec Biopharma at 10.98 subject to Rule 16b-3
 
Suvretta Capital Management, Llc over two months ago
Acquisition by Suvretta Capital Management, Llc of 2288 shares of Benitec Biopharma at 11.25 subject to Rule 16b-3
 
Suvretta Capital Management, Llc over two months ago
Acquisition by Suvretta Capital Management, Llc of 3142 shares of Benitec Biopharma at 10.98 subject to Rule 16b-3
 
Suvretta Capital Management, Llc over two months ago
Acquisition by Suvretta Capital Management, Llc of 4810 shares of Benitec Biopharma at 9.6 subject to Rule 16b-3
 
Suvretta Capital Management, Llc over three months ago
Acquisition by Suvretta Capital Management, Llc of 3076 shares of Benitec Biopharma at 10.22 subject to Rule 16b-3
 
Suvretta Capital Management, Llc over three months ago
Acquisition by Suvretta Capital Management, Llc of 1570 shares of Benitec Biopharma at 9.73 subject to Rule 16b-3
 
Mehta Kishan over six months ago
Insider Trading
 
Smith Edward F over six months ago
Acquisition by Smith Edward F of 12000 shares of Benitec Biopharma subject to Rule 16b-3
 
Megan Boston over six months ago
Acquisition by Megan Boston of 200004 shares of Benitec Biopharma at 5.21 subject to Rule 16b-3
 
Buchi J Kevin over a year ago
Acquisition by Buchi J Kevin of 35000 shares of Benitec Biopharma subject to Rule 16b-3
 
Megan Boston over a year ago
Purchase by Megan Boston of 25907 shares of Benitec Biopharma

Benitec Biopharma Outstanding Bonds

Benitec Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Benitec Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Benitec bonds can be classified according to their maturity, which is the date when Benitec Biopharma Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Benitec Biopharma Corporate Filings

10Q
14th of February 2025
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
13th of February 2025
Other Reports
ViewVerify
F3
3rd of January 2025
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
8K
31st of December 2024
An amendment to a previously filed Form 8-K
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Benitec Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Benitec Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Benitec Biopharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Benitec Biopharma Ltd Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.51)
Revenue Per Share
0.003
Quarterly Revenue Growth
0.125
Return On Assets
(0.50)
Return On Equity
(0.92)
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.